Shape Memory Medical’s President and CEO to present at LSI USA

Ted’s presentation will showcase unmet needs in aortic vascular conditions and describe how the development of shape memory polymer technology is positioned to address and provide meaningful solutions. Ted will highlight clinical milestones, including the AAA-SHAPE and FLAGSHIP aortic trials, as well as market potential and venture and partnership opportunities.

Presentation Details
March 19, 2025 at 3:10 – 3:19 pm PDT
Waldorf Astoria, Monarch Beach
Dana Point, California

The Company’s proprietary bioresorbable shape memory polymer offers a unique, more conformable solution that adapts seamlessly to the patient’s anatomy, filling the treatment area without exerting unnecessary force, compared with traditional metal embolization devices. Additionally, its radiolucent properties enhance imaging clarity during procedures and follow-up assessments, benefiting all imaging modalities.

“Shape Memory Medical’s smart polymer technology offers a different approach to embolization and opens the door to other innovative ideas that have the promise to be truly transformative,” explained Ruppel.

The Company’s IMPEDE and IMPEDE-FX Embolization Plugs are commercially used in over 30 countries. Shape Memory Medical is studying new clinical applications and has initiated AAA-SHAPE – Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion, a prospective, multicenter, randomized, open-label trial to determine the safety and effectiveness of the IMPEDE-FX RapidFill® Device to improve abdominal aortic aneurysm (AAA) sac behavior, when used with elective endovascular aneurysm repair (EVAR). Enrollment will continue through 2025. The company is also planning to launch its FLAGSHIP trial in 2025, building on initial first-in-human experience in Japan, to evaluate an innovative, large-diameter shape memory polymer system designed for false lumen embolization in aortic dissection.

About Shape Memory Medical

Shape Memory Medical Inc. is dedicated to developing innovative therapeutic solutions with its proprietary shape memory polymers, with devices approved in more than 30 countries spanning regions in Asia, the Middle East, Europe, the Americas and Australia. Neurovascular embolization products include the TrelliX® Embolic Coil, which is CE marked for use in the EU. Peripheral embolization products include the IMPEDE® and IMPEDE-FX Embolization Plugs and IMPEDE-FX RapidFill® Device. In countries recognizing CE marking, the IMPEDE and IMPEDE-FX Embolization Plugs and the IMPEDE-FX RapidFill are indicated to obstruct or reduce the rate of blood flow in the peripheral vasculature. In the United States, the IMPEDE Embolization Plug is indicated to obstruct or reduce the rate of blood flow in the peripheral vasculature, and the IMPEDE-FX Embolization Plug is indicated for use with the IMPEDE Embolization Plug to obstruct or reduce the rate of blood flow in the peripheral vasculature. The IMPEDE and IMPEDE-FX Embolization Plugs are PMDA approved in Japan. Caution: IMPEDE-FX RapidFill is an investigational device, limited by Federal (or United States) law to investigational use. For more information, visit www.shapemem.com.

Contacts